Global Acute Respiratory Distress Syndrome (ARDS) Market – Industry Trends and Forecast to 2030

Acute Respiratory Distress Syndrome (ARDS) Market Analysis and Size

Acute respiratory distress syndrome (ARDS) affects around one-third or (33%) of hospitalized patients, according to a study named "Acute respiratory distress syndrome in COVID-19: potential causes and therapeutic therapy" that was published in the Pneumonia in December 2021. Additionally, of the COVID-19 patients admitted to the intensive care unit, 75% (or nearly 3/4) have ARDS. The prognosis and fatality rate for ARDS patients with COVID-19 is not good. As a result, COVID-19 has dramatically impacted the market for acute respiratory distress. As a result, as more beds become available for treating ARDS patients, more hospitals will support segment expansion during the forecast period.

Data Bridge Market Research analyses that the acute respiratory distress syndrome (ARDS) market which is USD 129655.84 million in 2022, is expected to reach USD 279956.55 million by 2030, at a CAGR of 10.1% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Acute Respiratory Distress Syndrome (ARDS) Market Scope and Segmentation  

Market Definition

Acute respiratory distress syndrome (ARDS) is a potentially fatal lung injury that causes fluid to seep into the lungs. The majority of persons who develop ARDS are already in the hospital recovering from an injury or being treated for a condition such as COVID-19. The disease typically develops when fluids accumulate in the lungs' tiny, elastic air sacs or alveoli. Less oxygen reaches the bloodstream as a result of this fluid accumulation. The organs are deprived of getting adequate oxygen to operate normally as a result. Within a few hours to days following the initiating injury or infection, people with other illnesses will develop ARDS. Depending on the severity of the condition, a patient's chance of survival improves with age.

Acute Respiratory Distress Syndrome (ARDS) Market Dynamics

Drivers

• More Product Launches

A number of governments awareness campaigns are running to inform more people about the range of available diagnoses and treatments. Major market companies have introduced several items that have superior capabilities. For instance, in May 2021, Medtronic announced the release of the SonarMed airway monitoring system. Acoustic technology is used by this monitoring device to look for endotracheal tube occlusion. This accelerates market expansion.

• Rising need for ARDS treatment

The need for ARDS treatment is generated by an increase in hospital admissions and admissions to the critical care unit, which propels the market's expansion. 18.4% of patients with acute respiratory distress syndrome required re-hospitalization, according to a study titled "Acute respiratory distress syndrome readmissions: A countrywide cross-sectional analysis of epidemiology and costs of care" that was published in the PLOS One Journal in January 2022. Additionally, according to data from the Australian Institute of Health and Welfare published in May 2022, there were 11.8 million hospital admissions in 2020–21, an increase of 6.3% from 2019–20. Out of 11.8 million admissions, it was also reported that 7.0% of hospitalizations involved an ICU stay, 3.8% of hospitalizations involved respiratory disease, and 10.3% of hospitalizations had a separation mode indicating the patient passed away in the hospital. The market segment is anticipated to grow as a result of the rising number of admissions into emergency critical care, which creates a need for ARDS treatment.

Opportunities

• Increased Demand of Diagnosis

The market is expanding due to the increasing need for diagnoses. As many patients require several diagnoses in order for the treatment to be finished in a timely manner, the diagnosis sector is predicted to dominate the market. As a result, the market has huge opportunity.

Restraints/Challenges

• Lack of Skilled Professionals

The development of the global respiratory distress syndrome treatment market during the forecast period may be restrained by a lack of qualified specialists who are ignorant of the available treatment options for this illness.

• Increasing Cost of Treatment Therapeutics

Despite the fact that disease prevalence is rising, drug prices are also rising at the same time. These escalating treatment costs are restraining the market's expansion.

This acute respiratory distress syndrome (ARDS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acute respiratory distress syndrome (ARDS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Acute Respiratory Distress Syndrome (ARDS) Market

The COVID-19 pandemic epidemic affected the global economy. Respiratory illnesses such as pneumonia and acute respiratory distress syndrome gradually developed due to the disease's extreme infectiousness and contagiousness throughout the pandemic and even in the post-pandemic era. As a result, the COVID-19 pandemic led to significant rise in the global market for treatments for respiratory distress syndrome.

Recent Developments

• In 2021, SonarMed airway monitoring system's introduction was announced by Medtronic. To check for endotracheal tube obstruction, the system uses acoustic technology. The company's product line has grown as a result of this.
• In 2020, The SARS-CoV-2 fast antibody test was available, according to F. Hoffman-La Roche Ltd. Together with SD Biosenseor, Inc., the experiment was started. The company's product line has grown as a result of this.

Acute Respiratory Distress Syndrome (ARDS) Market Scope

The acute respiratory distress syndrome (ARDS) market is segmented on the basis of cause, type, route of administration, end user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cause

• Coronavirus Disease 2019 (COVID-19)
• Sepsis
• Inhalation of Harmful Substances
• Severe Pneumonia
• Others

Type

• Diagnosis
• Treatment

 Route of Administration

• Oral
• Parenteral
• Intramuscular
• Intravenous
• Others

 End User

• Hospitals
• Specialty Clinics
• Home Healthcare
• Others

Distribution Channel

• Direct Tender
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Acute Respiratory Distress Syndrome (ARDS) Market Regional Analysis/Insights

The acute respiratory distress syndrome (ARDS) market is analyzed and market size insights and trends are provided by cause, type, route of administration, end user, distribution channel as referenced above.

The countries covered in the acute respiratory distress syndrome (ARDS) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the acute respiratory distress syndrome (ARDS) market because of recent technological advancements and the availability of numerous cutting-edge pharmacological molecules to improve the therapeutic process.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 as a result of an increase in biotechnology research and centre activity.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Acute Respiratory Distress Syndrome (ARDS) Market Share Analysis

The acute respiratory distress syndrome (ARDS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acute respiratory distress syndrome (ARDS) market.

Some of the major players operating in the acute respiratory distress syndrome (ARDS) market are:

• F. Hoffmann-La Roche Ltd (Switzerland)
• Bayer AG (Germany)
• Sun Pharmaceutical Industries Ltd (India)
• Novartis AG (Switzerland)
• Drägerwerk AG & Co. KGaA (Germany)
• Fisher & Paykel Healthcare Limited (New Zealand)
• LivaNova PLC (U.K.)
• Besmed Health Business Corp. (Taiwan)
• Armstrong Medical (U.K.)
• Pfizer Inc. (U.S.)
• WEINMANN Emergency Medical Technology GmbH + Co. KG (Germany)
• Terumo Medical Corporation (U.S.)
• Getinge AB. (Sweden)
• EUROSETS (Italy)

SKU-59334